Cardiac toxicity with cisapride

Area of Science:

• Pharmacology
• Cardiology
• Drug Metabolism

Background:

• Cisapride is associated with serious cardiac arrhythmias like ventricular tachycardia and Q-T prolongation.
• These adverse events are particularly noted in patients co-administered cisapride with CYP3A4 inhibitors.
• Understanding cisapride's cardiac effects is crucial for patient safety.

Purpose of the Study:

• To review the mechanism of action of cisapride.
• To discuss the metabolism of cisapride, focusing on its interaction with the cytochrome P450-3A4 enzyme.
• To summarize reported cardiac adverse effects associated with cisapride, particularly with intravenous administration.

Main Methods:

• Literature review of cisapride's pharmacology and clinical adverse event reports.
• Analysis of drug interaction data concerning cytochrome P450-3A4 inhibition.
• Synthesis of information on cisapride metabolism and cardiac safety.

Main Results:

• Cisapride's mechanism involves enhancing gastrointestinal motility.
• Drug interactions with CYP3A4 inhibitors significantly alter cisapride metabolism.
• Reported cardiac adverse effects include ventricular tachycardia, ventricular fibrillation, torsades de pointes, and Q-T prolongation.

Conclusions:

• Concomitant use of cisapride with CYP3A4 inhibitors poses a significant risk for serious cardiac arrhythmias.
• Awareness of cisapride's metabolic pathway and potential drug interactions is essential for clinicians.
• Intravenous cisapride administration requires careful cardiac monitoring due to associated risks.